Celgene jumps towards empty psoriatic arthritis space
This article was originally published in Scrip
Executive Summary
In a late-breaking abstract session on November 13, 2012 at the American College of Rheumatology (ACR) 2012 meeting in Washington, DC, leading rheumatologist Professor Arthur Kavanaugh showcased data from the Phase III trial of Celgene’s Apremilast (CC-10004) in psoriatic arthritis (PsA).